You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • Reference number: TA268
  • Published:  12 December 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians joint NCRI Melanoma Group/RCR/ACP/JCCO

Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians joint NCRI Melanoma Group/RCR/ACP/JCCO Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians joint NCRI Melanoma Group/RCR/ACP/JCCO
02 November 2012
(301.54 Kb 27 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 31 October 2012

Back to top